Format

Send to

Choose Destination
See comment in PubMed Commons below
J Nucl Med. 2017 Apr;58(4):538-546. doi: 10.2967/jnumed.116.177659. Epub 2016 Dec 15.

Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.

Mayer AT1,2, Natarajan A2, Gordon SR3,4,5,6, Maute RL3,4,5,6, McCracken MN3,4,5,6, Ring AM7, Weissman IL3,4,5,6, Gambhir SS8,2,9.

Author information

1
Department of Bioengineering, Stanford University, Stanford, California.
2
Department of Radiology, Stanford University, Stanford, California.
3
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California.
4
Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University, Stanford, California.
5
Stanford Cancer Institute, Stanford University, Stanford, California.
6
Department of Pathology, Stanford University, Stanford, California.
7
Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut; and.
8
Department of Bioengineering, Stanford University, Stanford, California sgambhir@stanford.edu.
9
Department of Materials Science & Engineering, Stanford University, Stanford, California.

Abstract

Immune checkpoint blockade has emerged as a promising cancer treatment paradigm. Unfortunately, there are still a large number of patients and malignancies that do not respond to therapy. A major barrier to validating biomarkers for the prediction and monitoring of responders to clinical checkpoint blockade has been the lack of imaging tools to accurately assess dynamic immune checkpoint expression. Here, we sought to optimize noninvasive immuno-PET imaging of human programmed death-ligand 1 (PD-L1) expression, in a preclinical model, using a small high-affinity engineered protein scaffold (HAC-PD1). Six HAC-PD1 radiotracer variants were developed and used in preclinical imaging and biodistribution studies to assess their ability to detect human PD-L1 expression in vivo. Radiotracer design modifications included chelate, glycosylation, and radiometal. HACA-PD1 was adopted as the naming convention for aglycosylated tracer variants. NOD scid γ-(NSG) mice were inoculated with subcutaneous tumors engineered to either be constitutively positive (CT26 hPD-L1) or be negative (ΔmPD-L1 CT26) for human PD-L1 expression. When the tumors had grown to an average size of 1 cm in diameter, mice were injected with 0.75-2.25 MBq (∼10 μg) of an engineered radiotracer variant and imaged. At 1 h after injection, organs were harvested for biodistribution. Of the practical immuno-PET tracer modifications considered, glycosylation was the most prominent design factor affecting tracer uptake, specificity, and clearance. In imaging studies, aglycosylated 64Cu-NOTA-HACA-PD1 most accurately visualized human PD-L1 expression in vivo. We reasoned that because of the scaffold's small size (14 kDa), its pharmacokinetics may be suitable for labeling with the short-lived and widely clinically available radiometal 68Ga. At 1 h after injection, 68Ga-NOTA-HACA-PD1 and 68Ga-DOTA-HACA-PD1 exhibited promising target-to-background ratios in ex vivo biodistribution studies (12.3 and 15.2 tumor-to-muscle ratios, respectively). Notably, all HAC-PD1 radiotracer variants enabled much earlier detection of human PD-L1 expression (1 h after injection) than previously reported radiolabeled antibodies (>24 h after injection). This work provides a template for assessing immuno-PET tracer design parameters and supports the translation of small engineered protein radiotracers for imaging human immune checkpoints.

KEYWORDS:

PD-1; PD-L1; cancer immunotherapy; checkpoint blockade; immunoPET

PMID:
27980047
PMCID:
PMC5373501
[Available on 2017-10-01]
DOI:
10.2967/jnumed.116.177659
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center